Avidity biosciences announces the accelerated approval regulatory pathway in the u.s. is open for del-brax and initiates the global, confirmatory phase 3 forward™ study in fshd

-- planning accelerated approval bla submission in h2 2026, following topline data fromfortitude™ biomarker cohort in q2 2026 -- -- initiated global, confirmatory phase 3 forward ™ study of del-brax 2mg/kg every six weeks -- -- investor and analyst webcast event today, monday, june 9, 2025 at 8 a.m. et -- san diego , june 9, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™) to profoundly improve people's lives, today announced the accelerated approval regulatory pathway in the united states is open for delpacibart braxlosiran (del-brax) in the treatment of facioscapulohumeral muscular dystrophy (fshd).
RNA Ratings Summary
RNA Quant Ranking